In light of the strong link between LRRK2 and PD, in addition to the availability of a myriad of kinase inhibitors in chemical libraries from oncology programs, many pharmaceutical companies have LRRK2 kinase inhibitor programs. The gene discussed is LRRK2; the disease is Parkinson disease.